Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16077406 | 0.94 | FFAR4 (0.81) | FFAR4FFAR1 | |
| SCHEMBL16048670 | 0.92 | FFAR4 (0.81) | FFAR4FFAR1 | |
| SCHEMBL16077421 | 0.92 | FFAR4 (0.77) | FFAR4FFAR1 | |
| SCHEMBL16048892 | 0.91 | FFAR4 (0.79) | FFAR4FFAR1 | |
| SCHEMBL16049303 | 0.91 | FFAR4 (0.75) | FFAR4FFAR1 | |
| SCHEMBL16048720 | 0.89 | FFAR4 (0.86) | FFAR4FFAR1 | |
| SCHEMBL16049199 | 0.89 | FFAR4 (1.00) | FFAR4 | |
| SCHEMBL16864030 | 0.87 | FFAR4 (0.64) | FFAR4FFAR1 | |
| SCHEMBL16049388 | 0.87 | FFAR4 (0.78) | FFAR4FFAR1 | |
| SCHEMBL16049341 | 0.86 | FFAR4 (0.85) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | claimed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| EP-2970161-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015134039-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-11 | — | — | WO | disclosed |
| US-9067898-B1 | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067898-B1 | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014159054-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159054-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | FFAR4 54/4885FFAR1 20/4885 |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | FFAR4 54/4885FFAR1 20/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | FFAR4 54/4885FFAR1 20/4885 |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | FFAR4 54/4885FFAR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.